Investment Rating - The report assigns an "Add" rating for the company, marking its first coverage [2]. Core Insights - The company is a rare player in the "AI for Science" sector, founded by three MIT physicists in 2015, focusing on drug and material science R&D solutions using quantum physics principles, AI, and robotics. In H1 2025, the company achieved revenue of RMB 517 million, a year-on-year increase of 404%, with a net profit of RMB 83 million [6][10]. - The company signed the largest AI pharmaceutical order in the industry with DoveTree, valued at HKD 47 billion (USD 5.99 billion), which reflects its technological strength and potential for future business development [7]. - The company has made significant progress in drug discovery, with its AI platforms being applied across various fields and partnerships with major pharmaceutical companies like Johnson & Johnson and Pfizer [6][7]. Summary by Sections Company Overview - Latest closing price: HKD 11.35 - Total shares: 4.303 billion - Total market capitalization: HKD 48.8 billion - 52-week high/low: HKD 3.85 / HKD 15.12 - Debt-to-asset ratio: 8.9% - Price-to-earnings ratio: -226.34 [4]. Financial Performance - Revenue forecast for 2025-2027: RMB 787 million, RMB 998 million, RMB 1.465 billion, with growth rates of 195.3%, 26.8%, and 46.7% respectively. The net profit is projected to improve from -RMB 156 million in 2025 to RMB 196 million in 2027 [13][16]. Product Development - The company has developed two innovative topical ingredients for hair growth, Remeanagen™ and AquaKine™, which have received FDA approval and are expected to generate significant revenue in the consumer market [10][11]. - The global market for hair loss treatments is projected to grow from USD 5.04 billion in 2025 to USD 6.15 billion by 2033, indicating strong demand and growth potential [11]. Strategic Partnerships - The company has established a strategic partnership with JinkoSolar to develop a new generation of solar cells using AI and automation, enhancing its capabilities in the chemical raw materials sector [12][14].

Investment Rating - The investment rating for the company is "Buy" (首次) [5] Core Views - The company is expected to experience new growth drivers from its clean energy, LNG, and aerospace equipment sectors, with a record high backlog of orders [5][10] - The company operates under the CIMC Group, focusing on clean energy, chemical environment, and liquid food sectors, providing key equipment, engineering services, and system solutions [6] - The company anticipates revenue of 171.8 billion, 31.2 billion, and 44.5 billion from its three main business segments in 2024, with respective operating profits of 9.6 billion, 3.5 billion, and 3.5 billion [6] Summary by Relevant Sections Market Performance - The clean energy sector has seen a significant increase in new orders, with a total of 169.9 billion in new orders for the first three quarters of 2025, representing a year-on-year increase of 5.14% [7] - The backlog of orders in the clean energy sector is approximately 200 billion, with production scheduled until 2028 [7] - The company is positioned to benefit from the rising domestic natural gas consumption and the global shipping industry's transition to low-carbon alternatives [7] Clean Energy Projects - Key projects include the coke oven gas hydrogen co-production LNG project and biomass-based green methanol projects, which are expected to contribute significantly to revenue [8] - The company has ongoing projects with capacities of 100,000 tons of LNG and 15,000 tons of hydrogen, with expected production dates in 2024 and 2025 [8] Financial Forecasts - The company forecasts net profits of 12.2 billion, 14.6 billion, and 17.4 billion for 2025-2027, with respective growth rates of 11.5%, 19.6%, and 19.2% [10] - The current stock price corresponds to a price-to-earnings ratio of 15.3, 12.8, and 10.8 for the years 2025-2027 [10]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][6]. Core Viewpoints - The company is positioned as a leading OTA in the lower-tier market, benefiting from the release of pent-up demand and the enhancement of user value, which drives growth [3][11]. - The online travel market is characterized by strong certainty, with a stable competitive landscape allowing major players to release profits comfortably [2][11]. - The company has shown significant revenue growth, with a projected increase in revenue and net profit over the next few years, driven by the release of demand in the lower-tier market and refined operations [3][11]. Summary by Relevant Sections Company Overview - The company, Tongcheng Travel, was formed by the merger of Tongcheng Network and Elong in 2018, leveraging strengths in transportation ticketing and hotel bookings [1][14]. - It has over 250 million annual paying users, primarily in the lower-tier market, and has seen a significant recovery in performance post-pandemic [1][15]. Market Analysis - The domestic tourism market has rebounded, with tourist numbers and revenue recovering to 109% and 111% of 2019 levels, respectively, indicating a strong recovery trajectory [2][38]. - The OTA market is dominated by a few key players, with Ctrip holding over 50% market share and Tongcheng around 15%, suggesting a stable competitive environment [2][11]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 145.6 billion RMB, a year-on-year increase of 11%, with net profit rising by 41% to 22.9 billion RMB [1][24]. - The adjusted profit margin improved from 16.2% in Q1-Q3 2024 to 18.0% in the same period of 2025, reflecting operational efficiency [1][24]. Growth Drivers - The company is focusing on the lower-tier market, where there is significant potential for growth and increased online penetration in travel services [3][11]. - It is expanding its app and multi-channel traffic strategies, leading to a rise in average revenue per user and overall user engagement [3][11]. Financial Projections - Revenue projections for 2025-2027 are 193.0 billion RMB, 220.6 billion RMB, and 251.2 billion RMB, respectively, with net profits expected to reach 28.5 billion RMB, 33.4 billion RMB, and 39.0 billion RMB [3][5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 14.00, corresponding to a PE ratio of 14.6 times FY2026E [1][4]. Core Insights - The company showcased its significant position in the global AI industry during the Lenovo Tech World event, highlighting collaborations with major chip manufacturers like NVIDIA, AMD, Intel, and Qualcomm [1]. - The launch of the Lenovo Qira personal AI superintelligence marks a strategic shift from application-level to system-level AI, enhancing user engagement and creating a differentiated software ecosystem [3]. - The company is expected to benefit from the global upgrade of the AI hardware and software ecosystem, with projected non-HKFRS net profits of USD 1.664 billion, USD 1.854 billion, and USD 2.083 billion for FY26, FY27, and FY28 respectively, reflecting growth rates of 15.5%, 11.4%, and 12.4% [4]. Summary by Sections AI Infrastructure - The company launched a new AI inference server, ThinkSystem SR675i, in collaboration with AMD, optimized for large-scale data center scenarios [2]. - A partnership with NVIDIA was announced to establish an AI cloud super factory, leveraging NVIDIA's accelerated computing platform [2]. Personal AI Development - The Lenovo Qira personal AI superintelligence integrates seamlessly across Lenovo PCs, tablets, and Motorola devices, enhancing user experience with capabilities like context awareness and task switching [3]. Financial Projections - The company forecasts revenues of USD 75.844 billion, USD 83.447 billion, and USD 91.865 billion for FY26, FY27, and FY28, with respective growth rates of 9.8%, 10.0%, and 10.1% [9]. - Non-HKFRS EPS is projected to be USD 0.12, USD 0.14, and USD 0.15 for FY26, FY27, and FY28 [4].

Investment Rating - The report initiates coverage with an OUTPERFORM rating, indicating a positive outlook for the company [2]. Core Insights - Auntea Jenny (Shanghai) Industrial is recognized as a leading fresh beverage company in China, having surpassed 10,000 stores by the end of 2025, making it the third brand in the industry to achieve this milestone [3][7]. - The report emphasizes that the fresh beverage industry is increasingly dominated by leading brands, with strong channel advantages allowing them to rapidly expand and innovate [3]. - The company aims to become a global leader in multi-brand fresh beverage groups, leveraging a light-asset model for rapid expansion [7]. Financial Projections - Revenue projections for the company are as follows: Rmb 3,285 million for Dec-24, Rmb 4,215 million for Dec-25, Rmb 4,918 million for Dec-26, and Rmb 5,632 million for Dec-27, reflecting growth rates of -2%, 28%, 17%, and 15% respectively [2]. - Net profit is expected to grow from Rmb 418 million in Dec-24 to Rmb 707 million in Dec-27, with growth rates of 0%, 28%, 16%, and 14% [2]. - The diluted EPS is projected to increase from Rmb 4.09 in Dec-24 to Rmb 6.72 in Dec-27 [2]. Business Model and Strategy - The company operates under a dual-brand strategy, with Auntea Jenny as the main brand and Tea Waterfall as a supporting brand, focusing on both domestic and international markets [4][16]. - The report highlights the company's successful expansion in northern China, attributed to its management philosophy of mutual benefit and resource sharing, as well as a focus on health-oriented products targeting specific consumer demographics [4][20]. - The company has established a low-barrier franchise model, allowing for rapid store expansion and a diverse franchisee base, which is crucial for sustainable growth [37]. Market Position and Competitive Landscape - Auntea Jenny has shown a strong performance in the fresh beverage market, with a compound annual growth rate (CAGR) of 57% in store numbers from 2020 to 2023, outpacing competitors [8][20]. - The report notes that the company has a significant presence in the northern market, with over half of its stores located in this region, which is a strategic advantage compared to other brands [18][20]. - The competitive landscape is characterized by increasing market concentration, with leading brands expected to gain more market share while regional brands coexist [3][4]. Future Growth Potential - The company plans to open 2,000 to 3,000 new stores in 2026, maintaining a steady expansion pace while focusing on improving growth quality [53]. - The report anticipates that the Tea Waterfall brand will accelerate its expansion, targeting lower-tier cities and leveraging the established supply chain of the main brand [52]. - The overseas expansion strategy is focused on developed markets, with successful store openings in Malaysia, the USA, and South Korea, indicating significant growth potential [52].

Investment Rating - The investment rating for OSL Group is "Buy" (maintained) [1][7] Core Insights - The strategic acquisition of Banxa Holdings Inc. enhances OSL Group's compliance capabilities and global payment infrastructure, positioning the company for significant growth in the B2B sector [4][6] - OSL Group's revenue is projected to grow significantly, with estimates of HKD 514 million in 2025, HKD 873 million in 2026, and HKD 1.172 billion in 2027, reflecting growth rates of 37.12%, 69.91%, and 34.29% respectively [5][6] - The acquisition is expected to improve OSL's payment business revenue substantially, with Banxa's revenue for the first half of 2025 estimated at HKD 53.93 million [6] Financial Projections - Revenue projections for OSL Group are as follows: HKD 375 million for 2024, HKD 514 million for 2025, HKD 873 million for 2026, and HKD 1.172 billion for 2027 [5][7] - The forecasted net profit for OSL Group shows a loss of HKD 75.74 million in 2025, a slight loss of HKD 2.56 million in 2026, and a profit of HKD 194 million in 2027 [5][6] - The Price-to-Sales (P/S) ratio is expected to decrease from 29.90 in 2024 to 9.56 in 2027, indicating improved valuation as revenue grows [5][7]

Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Insights - The company is expected to see new developments in the upcoming Olympic cycle, with the launch of new store formats and product lines aimed at enhancing brand engagement and meeting diverse consumer needs [2][9]. - The earnings per share (EPS) forecasts for 2025, 2026, and 2027 have been slightly adjusted to 0.95, 1.07, and 1.22 RMB respectively, with a target price set at 25.41 HKD based on a 24x valuation for 2025 [3][10]. - The company has shown resilience in a challenging consumer environment, with expectations for slight revenue growth driven by specific product categories and improved operational efficiency [9]. Financial Summary - Revenue projections for the company are as follows: - 2023: 27,598 million RMB - 2024: 28,676 million RMB (growth of 3.9%) - 2025: 29,101 million RMB (growth of 1.5%) - 2026: 30,640 million RMB (growth of 5.3%) - 2027: 32,747 million RMB (growth of 6.9%) [4]. - Operating profit and net profit forecasts indicate a decline in 2025, with operating profit expected to be 3,331 million RMB and net profit at 2,465 million RMB, before recovering in subsequent years [4]. - The company’s gross margin is projected to remain stable, with estimates of 48.8% in 2025 and gradually increasing to 49.2% by 2027 [4]. - The price-to-earnings (P/E) ratio is forecasted to be 18.6 in 2025, decreasing to 14.6 by 2027, indicating a potential improvement in valuation over time [4].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is positioned as a leading player in the high-end beauty and health management sector, with a well-established "Double Beauty + Double Health" ecosystem that drives growth through both organic and external expansion [8][13]. - The company has demonstrated strong revenue growth, with total revenue projected to increase from 21.45 billion in 2023 to 45.78 billion by 2027, reflecting a compound annual growth rate (CAGR) of 11.3% from 2020 to 2024 [25]. - The net profit attributable to shareholders is expected to rise from 2.16 billion in 2023 to 5.18 billion by 2027, with significant year-on-year growth rates [1][25]. Summary by Relevant Sections Company Overview - The company, established in 1993, has evolved from a lifestyle beauty business to a comprehensive beauty and health management service provider, encompassing traditional beauty, medical beauty, and sub-health assessment services [8][13]. - It has developed four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its market position through acquisitions of Nai Rui Er and Si Yan Li [13][20]. Financial Analysis - The company's revenue has shown resilience, increasing from 15.03 billion in 2020 to 25.72 billion in 2024, with a notable 28.2% growth in the first half of 2025 [25][28]. - The gross profit margin has improved from 46.57% in 2020 to 49.33% in the first half of 2025, indicating effective cost control and a higher proportion of high-margin services [28][30]. Industry Insights - The beauty and health management market is expected to grow significantly, with the traditional beauty market projected to reach 640.2 billion by 2030, and the light medical beauty market expected to expand to 415.7 billion [40][44]. - The sub-health medical service market is identified as a high-potential area, with a projected market size of 290 billion by 2030, driven by increasing awareness and demand for preventive health services [48][51]. Competitive Advantages - The company's business model leverages strong synergies between its various service lines, enhancing customer conversion rates and operational efficiency [8][13]. - The management team possesses extensive experience in the beauty and health industry, which supports the company's strategic initiatives and operational execution [22][24].

Investment Rating - The report does not explicitly provide an investment rating for WuXi AppTec [2][3]. Core Insights - The report highlights three major catalysts that may drive WuXi AppTec's stock performance in Q1 2026: 1) Updates from the industry summit scheduled for January 12-15, which is expected to support the CRO industry's outlook; 2) The release of the 1260H list in January-February 2026, which should alleviate the impact of pending policy decisions; 3) The company's full-year guidance for 2026, to be announced in March 2026 [5]. - The report indicates that in 2026, the focus for the Chinese healthcare sector will shift towards earnings realization rather than valuation multiple expansion, with WuXi AppTec expected to lead in visibility of earnings growth [7]. - The report anticipates a recovery in outsourcing demand in 2026 due to the resolution of policy and tariff uncertainties, which had previously delayed biotech financing and new R&D initiatives in 2025 [6]. Summary by Sections Company Overview - WuXi AppTec is a global enterprise with operations across Asia, Europe, and North America, providing a comprehensive range of R&D and manufacturing services to advance the pharmaceutical and healthcare industries [10]. - The company covers the entire drug development cycle through five core business segments: small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics [10]. Revenue Breakdown - Revenue by product category: Chemical business (72.3%), Testing business (16.2%), Biological business (6.3%), High-end therapeutic CTDMO (3.2%) [11]. - Revenue by region: Middle East and Africa (8.7%), Asia (36.5%), Europe (27.3%), Americas (27.5%) [11]. Stock Information - Stock price as of January 5, 2026: 104.2 HKD - Market capitalization: 40.33 billion USD - Consensus target price (Refinitiv): 130.76 HKD [13].

Investment Rating - The report maintains an "Outperform" rating for Mao Geping Cosmetics, with a target price of HKD 108.20, indicating a potential upside of 23.1% from the current price of HKD 87.95 [2][14]. Core Insights - The cosmetics industry has seen intensified competition since 2025, a trend expected to continue into 2026. Mao Geping is anticipated to sustain strong growth in the second half of 2025, driven by robust offline same-store sales and strong online growth, despite some weakening in household consumption [3][11]. - The company has signed a strategic partnership with L Catterton, aimed at global market expansion and establishing a premium beauty investment fund, which could enhance its brand penetration in overseas markets [4][12]. - Shareholders plan to reduce their holdings by up to 3.51% of the total share capital, which may temporarily affect market sentiment, but the company emphasizes that this will not change control and the long-term fundamentals remain strong [5][13]. Financial Performance Summary - Revenue projections for Mao Geping are RMB 5.101 billion for 2025, RMB 6.489 billion for 2026, and RMB 8.115 billion for 2027, reflecting year-on-year growth rates of 31.3%, 27.2%, and 25.0% respectively [3][11]. - Net profit attributable to the parent company is expected to be RMB 1.201 billion in 2025, RMB 1.494 billion in 2026, and RMB 1.848 billion in 2027, with growth rates of 36.4%, 24.4%, and 23.7% respectively [3][11]. - The company maintains a high gross profit margin of around 84% and a return on equity (ROE) of approximately 34.9% in 2024, projected to decrease slightly in the following years [9][10].